A Phase Ib Clinical Study of BBI608 for Adult Patients With Advanced, Refractory Hematologic Malignancies

Trial Profile

A Phase Ib Clinical Study of BBI608 for Adult Patients With Advanced, Refractory Hematologic Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Napabucasin (Primary) ; Dexamethasone
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Boston Biomedical
  • Most Recent Events

    • 20 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 01 Apr 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2018, as reported by ClinicalTrials.gov.
    • 14 Oct 2015 Treatment arms changed from 5 to 8 and planned number of patients changed from 80 to 200 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top